Ivabradine NDC 72205-336

NDC codes

FDA NDC Directory

Product NDC (as listed)72205-336Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72205-0336Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72205-336-18	72205033618	180 TABLET, FILM COATED in 1 BOTTLE (72205-336-18)Marketed from Jul 1, 2025
72205-336-60	72205033660	60 TABLET, FILM COATED in 1 BOTTLE (72205-336-60)Marketed from Jul 1, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ivabradine
Generic name (nonproprietary): ivabradine
Active ingredients: Ivabradine hydrochloride — 5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Novadoz Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213483
Marketing start: Apr 28, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists (Mechanism)
Identifiers: Product ID 72205-336_c154911d-3174-409f-9619-3fe38dda4dbdSPL ID c154911d-3174-409f-9619-3fe38dda4dbdSPL set ID 676907d3-b374-4baa-8422-c04706409540RxCUI 1649485, 1649493UNII TP19837BZKUPC 0372205337183, 0372205337602, 0372205336186, 0372205336605
Pharmacologic class: Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472205033618 followed by a unit qualifier and the quantity

Package 72205-0336-18. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 20, 2026.

Indications (excerpt from the label)

Ivabradine tablets are a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) 1.1 Heart Failure in Adult Patients Ivabradine tablets are indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213483

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213483
Product	Strength	Form · route	Labeler	Product NDC
Ivabradine	Ivabradine hydrochloride 7.5 mg/1	Tablet, Film coatedOral	Northstar Rx LLC	72603-935
Ivabradine	Ivabradine hydrochloride 5 mg/1	Tablet, Film coatedOral	Northstar Rx LLC	72603-934
Ivabradine	Ivabradine hydrochloride 7.5 mg/1	Tablet, Film coatedOral	Novadoz Pharmaceuticals LLC	72205-337